Repros reported additional topline results from study for Androxal Repros Therapeutics reported additional topline results for study ZA-302, the second pivotal efficacy study for Androxal. The results of both pivotal studies, ZA-301 and ZA-302, have met the SPA co-primary endpoints as defined by the FDA, the company said. Study ZA-302 had no detected site anomalies. The company said it is completely satisfied that all data entered into the data base for study ZA-301 will pass any scrutiny the FDA chooses to apply. The company said, "We are confident in the reliability of our results and the positive outcomes of our two pivotal clinical trials. Our style with the investment community has always been direct and honest and we are happy to provide this additional data for investor review."
News For RPRX From The Last 14 Days
Check below for free stories on RPRX the last two weeks.
On The Fly: Analyst Initiation Summary Today's noteworthy initiations include: Altisource Residential (RESI) initiated with a Buy at Deutsche Bank... Cedar Fair (FUN) initiated with an Outperform at FBR Capital... Chimerix (CMRX) initiated with an Overweight at Piper Jaffray... GW Pharmaceuticals (GWPH) initiated with an Overweight at Piper Jaffray... Insmed (INSM) initiated with an Overweight at Piper Jaffray... Merchant Bancshares (MBVT) initiated with a Buy at Sterne Agee... Nektar (NKTR) initiated with an Overweight at Piper Jaffray... Oi S.A. (OIBR) initiated with an Outperform at Bernstein... Qunar (QUNR) initiated with a Hold at Deutsche Bank... Repros Therapeutics (RPRX) initiated with an Overweight at Piper Jaffray... Ruckus Wireless (RKUS) initiated with a Buy at Stifel... SeaWorld (SEAS) initiated with a Market Perform at FBR Capital... Six Flags (SIX) initiated with a Market Perform at FBR Capital... Twitter (TWTR) initiated with a Buy at MKM Partners... Surgical Care Affiliates (SCAI) initiated with a Buy at SunTrust.